ARCHIVES

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

ODAC Reviews Post-Marketing Studies for Eight Indications

March 21, 2003

Clinical Trials Streamlining Moves Forward; NCI Commits To Full Funding For Groups

October 9, 1998

CTEP Analyses Proposals For Changes In Cooperative Groups

April 25, 1986

Caterpillar In. Benefits Plan To Cover Entry On BMT trials

June 14, 1996

Clinical Trials: NCI Issues Clinical Alert On Chemo For Cervical Cancer

February 26, 1999

Doubling Budget For NSF High Priority For FASEB.

April 20, 2001